case_images: PMC6803543_01
case_images: Histological evaluation of the patent's tumor. (A) Hematoxylin and eosin staining microphotograph. (B) Immunohistochemical staining for TTF-1 (SPT24). (C) Immunohistochemical staining for p40 (DeltaNp63). (D) FISH analysis for ALK-EML4 translocation.
case_images: fonc-09-01026-g0001.jpg
case_images: PMC6803543_01_fonc-09-01026-g0001.jpg
case_images: F1
case_images: ALK translocation was detected using FISH (Figure 1).
case_images: PMC6803543_02
case_images: PMC6803543_03
case_images: PMC6803543_04
case_images: MRI evaluation of brain metastases dynamics at therapy lines 3 and 4 after development of the ceritinib resistance. Treatment regimens were pemetrexed + cisplatin (2015.04.03), topotecan followed by crizotinib (2015.07.20) and crizotinib + bevacizumab (2016.11.25). (A) Lesion 1, right temporoparietal region. (B) Lesion 2, right occipital lobe. (C) Lesion 3, right occipital lobe.
case_images: fonc-09-01026-g0002.jpg
case_images: PMC6803543_05_fonc-09-01026-g0002.jpg
case_images: F2
case_images: This resulted in a decrease of several brain lesions (Table 1, MRI 2016.08.04, 2016.10.24, and 2016.11.25; Figure 2, 2016.11.25).
case_images: PMC6803543_05
case_images: MRI evaluation of brain metastases dynamics at therapy lines 3 and 4 after development of the ceritinib resistance. Treatment regimens were pemetrexed + cisplatin (2015.04.03), topotecan followed by crizotinib (2015.07.20) and crizotinib + bevacizumab (2016.11.25). (A) Lesion 1, right temporoparietal region. (B) Lesion 2, right occipital lobe. (C) Lesion 3, right occipital lobe.
case_images: fonc-09-01026-g0002.jpg
case_images: PMC6803543_05_fonc-09-01026-g0002.jpg
case_images: F2
case_images: This resulted in a decrease of several brain lesions (Table 1, MRI 2016.08.04, 2016.10.24, and 2016.11.25; Figure 2, 2016.11.25).
case_images: PMC6803543_06
case_images: PMC6803543_07